The Infectious Disease Research Team at the University Hospital of Liverpool Group (UHLG) recently recruited the 50,000th participant to the international RECOVERY trail. This is a significant milestone, with the UHLG having been a top recruiter to the study over the years.
Originally launched in 2020 during the COVID-19 pandemic, the trial aimed to evaluate the effectiveness of alternative treatments for the virus.
Research delivery teams from across UHLG have been supporting the RECOVERY study throughout its duration, bringing together medical professionals from different departments to collaborate on this vital research.
Fast forward to 2025, the study has broadened its focus. In addition to COVID-19, RECOVERY now investigates treatments for influenza (flu) and community-acquired pneumonia. This expansion reflects the trial’s ongoing commitment to improving patient outcomes for a wider range of respiratory illnesses.
The research team has worked tirelessly to ensure patient access to the study. By testing new treatments against standard care, RECOVERY continues to shape how these illnesses are managed. The findings are expected to lead to better recovery rates, improved rehabilitation, and more effective treatment protocols.
Pictured: The Infectious Disease Research team currently working on RECOVERY.
This milestone marks a major step forward in the fight against infectious diseases, offering hope for more effective therapies in the future.